A diagnosis doesn't mean there's nothing left to do.
Across generations, humanity has too often mistaken the early whispers of cognitive change for the ordinary noise of aging — and in that dismissal, lost precious time. Preventive neurologist Richard Isaacson is working to reframe this habit of mind, arguing that Alzheimer's and related decline are not inevitable fates but medical conditions responsive to intervention, much like heart disease or diabetes. His message, grounded in research and sharpened by personal witness, is that the window to act is wider than most people believe — but only if they choose to look through it.
- Forgotten rooms and repeated sentences are being waved away as normal aging, even as the science shows these moments can be the earliest, most actionable signals of cognitive change.
- At least 5% of cognitive decline cases have fully reversible causes — vitamin deficiencies, thyroid dysfunction, hormonal imbalance — meaning some people are living with treatable conditions that go unaddressed for years.
- Blood biomarker testing offers new diagnostic promise, but sample handling, timing, and lab quality can dramatically skew results, leaving patients vulnerable to false reassurance or unnecessary alarm.
- The most powerful tools available right now are behavioral — sleep architecture, daily exercise, hearing restoration, and metabolic health — each one a lever that can meaningfully shift the brain's long-term trajectory.
- For women, the perimenopausal window is emerging as a critical and underutilized moment for intervention, with hormone therapy and body composition tracking offering concrete pathways to reduce risk.
- Anti-amyloid drugs remain selective and contested, but a diagnosis is no longer a closed door — the question is whether people will seek evaluation early enough to keep their options open.
Richard Isaacson, a preventive neurologist at Atria Health, wants people to stop normalizing the small cognitive slips they notice in themselves. Repeating a story, losing a thought mid-sentence, walking into a room and forgetting why — these moments are too often blamed on stress or age and quietly set aside. Isaacson argues this habit of dismissal has a cost, and his own family paid part of it. A relative began showing signs of cognitive change in 2007, but her doctors called it normal aging. Even with Isaacson advocating directly on her behalf, an Alzheimer's diagnosis took years to arrive — and with it, a narrowed window for early action.
His central reframe is this: Alzheimer's is not primarily a brain disease but a medical condition, one that responds to the same preventive logic applied to heart disease or diabetes. That means cognitive decline is neither inevitable nor beyond reach. A basic evaluation — physical exam, neurological screening, possibly a brain MRI — can rule out reversible causes, which account for at least 5% of cases. It can also distinguish between genuine memory loss and the cognitive overwhelm that mimics it. A 15-minute screening establishes a baseline that becomes a reference point for years ahead.
Blood biomarker testing has emerged as a useful tool for those already experiencing symptoms, but Isaacson is candid about its fragility. Sample handling, transit conditions, timing relative to illness, and lab equipment all affect accuracy. His own practice takes elaborate precautions — nasal swabs to rule out active infection, restricted collection days to avoid weekend degradation, duplicate testing, and long-term frozen storage. For those testing elsewhere, his guidance is straightforward: if results concern you, verify them with a second test and a specialist.
The most powerful interventions, however, remain behavioral. His research found that people sleeping more than seven hours performed measurably better cognitively, with REM sleep enabling the brain's glymphatic system to clear disease-associated proteins. Exercise loosens amyloid during the day; sleep removes it at night. Hearing loss — responsible for 8% of dementia cases — should be treated as a preventable risk factor, not an accepted feature of aging. Hearing aids, in this framing, are a brain health tool.
For women, perimenopause is a window that demands particular attention. Two in three Alzheimer's brains belong to women, and the estrogen drop during this transition appears to matter. Hormone replacement therapy, body composition tracking, and metabolic monitoring are among the most effective tools available during this period. On the pharmaceutical side, anti-amyloid infusions remain selective and their long-term effects still under study, but Isaacson has observed patients regain cognitive function after diagnosis — and he is careful not to call that a ceiling.
The message he returns to is neither catastrophic nor comforting in a false way: the window is open, but it will not stay open indefinitely. Whether the signal is a forgotten word or a family history, the time to act is before certainty arrives — not after.
You notice you're repeating yourself. You forget why you walked into a room. You blame it on stress, on too much screen time, on getting older. Richard Isaacson, a preventive neurologist at Atria Health and one of the field's leading voices on Alzheimer's prevention, wants you to stop dismissing these moments. More importantly, he wants you to understand that the window to act on them is far wider than most people realize.
Isaacson reframes how we think about cognitive decline entirely. Alzheimer's, he argues, is not primarily a brain disease but a medical condition—one that responds to the same preventive tools we use against heart disease or diabetes. This shift in perspective matters because it means cognitive decline is not inevitable, and it is not beyond intervention. The problem is that we've normalized the early warning signs. Isaacson's own family learned this the hard way. His father's cousin began repeating herself in 2007, but her doctors dismissed it as normal aging. Even with Isaacson advocating directly to her primary care physician, it took years before she received an Alzheimer's diagnosis. By then, the window for early intervention had narrowed considerably.
This is precisely the pattern Isaacson wants to break. Seeking medical evaluation for cognitive changes does not mean catastrophizing. It means getting a basic screening to rule out treatable causes. At least 5 percent of cognitive decline cases stem from something reversible—a vitamin deficiency, thyroid dysfunction, hormonal imbalance, or infection. A physical exam, neurological assessment, and possibly a brain MRI can clarify what is actually happening. Equally important is distinguishing between attention problems and memory problems. Many people struggle with information overload or focus, which gets misinterpreted as early Alzheimer's when it is simply cognitive overwhelm. A 15-minute screening in a doctor's office can establish this baseline and provide a reference point for years to come.
Blood biomarker testing has emerged as a promising tool for people already experiencing cognitive symptoms, helping determine whether changes reflect Alzheimer's pathology. But Isaacson is transparent about the limitations. Sample handling matters enormously—whether it traveled on dry ice, how long it sat in transit, whether the person was ill at the time of the draw, which machine processed it. His own lab takes extraordinary precautions: nasal swabs on every patient to rule out active infection (which can falsely elevate brain inflammation markers), samples accepted only Monday through Wednesday to prevent weekend delays that degrade quality, duplicate testing for verification, and perpetual storage at negative 80 degrees as the science evolves. For those testing outside specialized labs, his advice is simple: if results worry you, verify them. Get a second test. Consult another brain health expert. He has developed free resources at retainyourbrain.com and ind.org/bloodtest to help people interpret results responsibly.
But the most powerful interventions are not pharmaceutical. They are behavioral. Isaacson's research using wearable data found that people sleeping more than seven hours and eleven minutes per night performed better cognitively than those sleeping less. Sleep, particularly REM sleep, is when the brain's glymphatic system—essentially its waste-removal network—clears out disease-causing cells. Exercise during the day loosens amyloid, the sticky protein that accumulates in Alzheimer's brains. Sleep removes it at night. He recommends aiming for at least one hour and fifteen to twenty minutes of deep and REM sleep respectively to give the brain sufficient time for this clearing process. Hearing loss, often overlooked, accounts for 8 percent of dementia cases, with 45 percent of those cases potentially preventable through hearing restoration. Hearing aids should be viewed not as a sign of aging but as a preventative tool.
For women, perimenopause represents a critical window. Two of every three Alzheimer's brains belong to women, and research points to the connection between menopause and dementia risk. The rapid drop in estrogen during perimenopause is a moment when intervention becomes especially powerful. Hormone replacement therapy emerges as one of the most effective tools available during this transition. Body composition also matters—visceral fat, muscle mass, and bone density (which Isaacson describes as a proxy for brain health) should be tracked over time using tools like DEXA scans and body composition scales.
On the pharmaceutical side, anti-amyloid drugs delivered by infusion have generated both hope and controversy. In the right patient at the right dose, Isaacson uses them selectively. He avoids claiming they can reverse Alzheimer's, but he has observed patients regain cognitive abilities after diagnosis. Whether those gains persist long-term remains an open question. What he states with confidence is that a diagnosis does not mean the end of options. People can manage their risk factors whether they have symptoms or not. They can exercise, stabilize blood sugar, see doctors regularly, and access both symptomatic and potentially disease-modifying therapies.
The core message is urgent but not alarmist: cognitive decline is not something to wait on. The earlier you act, the more options remain available. From a basic cognitive screen to understanding blood biomarkers to managing sleep, exercise, hearing, and metabolic health, there are concrete steps at every stage. If something feels off, see a doctor. Get a baseline. Start addressing what is within your control. The window is open. The question is whether you will use it.
Citações Notáveis
Alzheimer's is a medical disease that affects the brain as the end organ—not a primary brain disease, but a medical condition you can fight with the same tools you'd use to manage any other health problem.— Richard Isaacson, preventive neurologist
During the perimenopause transition, that rapid drop of estrogen for women is a critical window of opportunity. That's when a woman has to do something.— Richard Isaacson
A Conversa do Hearth Outra perspectiva sobre a história
Why does Isaacson keep emphasizing that this isn't primarily a brain disease? That seems like a semantic distinction.
It's not semantic at all. If Alzheimer's is a primary brain disease, it feels isolated, untreatable, something that happens to you. If it's a medical condition like diabetes or hypertension, it becomes something you can manage with the tools you already know—sleep, exercise, metabolic control, regular checkups. It shifts you from passive to active.
But people have been ignoring cognitive changes for decades. Why would framing it differently suddenly make them act?
Because Isaacson is also saying something else: you have time. His father's cousin waited years for a diagnosis. But if you catch it early, 5 percent of cases are reversible. That's not nothing. It's a reason to show up.
The blood biomarker testing sounds promising, but he seems almost skeptical of it.
He's skeptical of the hype around it. The science is real, but the execution is fragile. A sample shipped on the wrong day, a person who was sick when tested—these things matter. He's being honest about what the test can and cannot tell you right now.
What strikes you most about the sleep data he mentions?
That it's so specific. Seven hours and eleven minutes. Not eight, not seven. That precision suggests he's looked at actual data, not just repeating conventional wisdom. And the mechanism—that sleep clears amyloid—makes the whole thing feel less like advice and more like biology you can work with.
The perimenopause angle for women seems almost like an afterthought in the article.
It shouldn't be. Two out of three Alzheimer's brains are women's brains. That's not an afterthought. That's a crisis that gets treated like one. Isaacson is saying there's a specific window—the estrogen drop—where intervention is most powerful. That's not generic advice. That's actionable.